Hester Biosciences Ltd. demonstrates moderate growth and profitability metrics compared to its peers. While it has a respectable debt-to-equity ratio, it trails behind top performers in revenue growth and efficiency. Value picks are identified among peers with better margins and lower valuation metrics, while several companies exhibit financial weaknesses.

• • Hester Biosciences has moderate EPS growth but lower revenue growth compared to peers.
• • Cipla Ltd. emerges as a strong value pick with lower valuation metrics and decent profitability.
• • Divi's Laboratories and Sun Pharma are identified as financially stressed with high valuations and lower growth rates.